HMPL 002

Drug Profile

HMPL 002

Alternative Names: HMPL-002

Latest Information Update: 04 Feb 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hutchison MediPharma
  • Class Antineoplastics; Chemosensitisers; Radiation-sensitising agents; Radiosensitisers
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Head and neck cancer
  • Suspended Non-small cell lung cancer

Most Recent Events

  • 04 Feb 2009 Suspended - Phase-I for Head and neck cancer in USA (PO)
  • 04 Feb 2009 Suspended - Phase-II for Non-small cell lung cancer in China (PO)
  • 04 Feb 2009 Interim efficacy & adverse events data from a phase II trial in Non-small cell lung cancer released by Chi-Med
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top